Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first‐line treatment of advanced esophageal squamous cell carcinoma-Reference-Cited by-同舟云学术

Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first‐line treatment of advanced esophageal squamous cell carcinoma

Published:2020-12 Issue:12 Volume:40 Page:711-720
ISSN:2523-3548
Container-title:Cancer Communications
language:en
Short-container-title:Cancer Communications

Author:

Zhang Bo¹,Qi Ling¹,Wang Xi¹,Xu Jianping¹,Liu Yun¹,Mu Lan¹,Wang Xingyuan¹,Bai Lidan²,Huang Jing¹^ORCID

Affiliation:

1. Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100021 P. R. China

2. Jiangsu Hengrui Medicine Co. Ltd. Lianyungang Jiangsu 222047 P. R. China

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cac2.12119

Reference33 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Global incidence of oesophageal cancer by histological subtype in 2012

3. Systemic therapy for esophageal cancer: chemotherapy

4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology.Esophageal and Esophagogastric Junction Cancers Version 4. 2020 – August 14 2020.https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed Oct 3 2020.

5. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of Neoadjuvant Chemoradiotherapy versus Chemoradiotherapy Plus Immunotherapy for Esophageal Squamous Cell Carcinoma in a Real-World Multicenter Cohort: A Propensity Score Matching Study;2024-09-09

2. Enhancing cancer immunotherapy and antiangiogenic therapy by regulating gut microbes: Opportunities and challenges;MedComm – Oncology;2024-08-08

3. First-line treatment with KN046, chemotherapy and palliative radiotherapy for advanced esophageal squamous cell carcinoma: an open-label, dose escalation, and dose expansion phase Ib trial;Cancer Immunology, Immunotherapy;2024-08-06

4. Neoadjuvant chemotherapy combined with immunotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma;The Journal of Thoracic and Cardiovascular Surgery;2024-08

5. Therapeutic implications of signaling pathways and tumor microenvironment interactions in esophageal cancer;Biomedicine & Pharmacotherapy;2024-07